Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 3,104 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 3,104 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $77.09, for a total transaction of $239,287.36. Following the transaction, the chief financial officer owned 108,065 shares of the company’s stock, valued at $8,330,730.85. This represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD traded down $0.78 during trading on Thursday, hitting $75.96. The company had a trading volume of 2,749,530 shares, compared to its average volume of 2,009,908. The firm has a market capitalization of $14.68 billion, a price-to-earnings ratio of -14.69 and a beta of 0.96. The stock has a fifty day simple moving average of $65.55 and a two-hundred day simple moving average of $48.76. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $81.49.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period in the previous year, the business posted ($0.94) EPS. On average, research analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors have recently added to or reduced their stakes in RVMD. General Atlantic L.P. purchased a new stake in Revolution Medicines in the 3rd quarter valued at $115,556,000. Norges Bank purchased a new position in shares of Revolution Medicines during the 2nd quarter worth $62,584,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Revolution Medicines during the 1st quarter valued at about $59,173,000. Nextech Invest Ltd. boosted its position in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in shares of Revolution Medicines in the second quarter valued at about $44,148,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RVMD. Royal Bank Of Canada started coverage on Revolution Medicines in a report on Monday, November 3rd. They set an “outperform” rating and a $77.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Wednesday, October 8th. Wolfe Research started coverage on Revolution Medicines in a report on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on shares of Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Needham & Company LLC upped their target price on shares of Revolution Medicines from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Revolution Medicines presently has an average rating of “Buy” and an average price target of $78.50.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.